

IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: UENO 12

In re Application of:)	Conf. No.: 6639
)	
Takashi UENO et al.)	Art Unit:
)	
IA No. PCT/JP2004/012172)	
)	
IA Filed: August 25, 2004)	Examiner:
)	
U.S. Appln. No.: 10/569,814)	Washington, D.C.
)	
For: METHOD OF SEARCHING FOR)	May 30, 2006
FUNCTIONAL NUCLEOTIDE)	
MOLECULE)	

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

☒ B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR \$1.114.

☒ 2. In accordance with 37 CFR \$1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR \$1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached below:

☐ A. Document(s) _____ is deemed substantially cumulative to document(s) _____, and, in accordance with 37 CFR \$1.98(c), a copy of each of the former document(s) is not enclosed.

☐ B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR \$1.98(d). Per 37 CFR \$1.98(d), copies of these documents need not be filed in this application.

☒ 3. Document(s) AC is not in the English language. In accordance with 37 CFR \$1.98(a)(3), Applicant states:

☐ An English translation of each document _____ (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] For documents AC, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.

[X] A concise explanation of the relevance of document(s) AC is found in the attached International search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of document(s) _____ is set forth as follows:

[] A concise explanation of the relevance of document(s) _____ can be found on page(s) _____ of the specification.

[] A concise explanation of the relevance of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

In re Appln. No. 10/569,814

Respectfully submitted,


BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:



Anne M. Kornbau
Registration No. 25,884

AMK:srd
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\BN\A\Aoyb\Ueno12\Pto\2006-05-30 IDS.doc



BN/SB/08A/B

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/569,814
Filing Date	February 28, 2006
First Named Inventor	Takashi UENO et al
Group Art Unit	
Examiner Name	
Attorney Docket Number	UENO 12

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2002/0002278 A1	01-03-2002	NILSEN, et al.	
	AB	US-2004/0106565 A1	06-03-2004	ODENTHAL, et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	AC	WO 2002/04509 A2	01-17-2002	CELL CENTER COLOGNE GmbH		
	AD	WO 2002/16944 A2	02-28-2002	PROMEGA CORPORATION		
	AE	WO 2002/34940 A2	05-02-2002			
	AF	WO 2004/076629 A2	09-10-2004	NUCLEONICS INC.		

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AG	DOENCH, John G., "siRNAs can Function as miRNAs", Gene & Development, February 15, 2003, p. 438-442, Vol. 17, No. 4	
	AH	SONG, Erwei et al., "RNA Interference Targeting Fas Protects Mice from Fulminant Hepatitis", March 2003, p. 347-351, Vol. 9, No. 3	
	AI	YOKOTA, T. et al., "Inhibition of intracellular hepatitis C virus replicaiton by synthetic and vector-derived small interfering RNAs", EMBO Reports, January 2003, p. 602-608, Vol. 4, No. 6	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.